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Abstract  
Background: Giant cell tumor of bone (GCTB) is an osteolytic, locally aggressive, rarely 
metastazing bone tumor. This is a retrospective study evaluating a large series of GCTB 
patients treated with denosumab in routine practice in 6 European reference centers.  
Methods: Patients with locally advanced, unresectable or metastatic GCTB, treated with 
denosumab outside clinical trials were eligible. Primary end-point was  progression-free 
survival (PFS) for all patients; secondary end-points were: type of surgery, relapse rate and 
event-free survival for patients after preoperative denosumab + surgery. 
Results: We identified 138 patients treated in the period 2011-2016.  In 40/43 cases the 
diagnosis was confirmed by H3F3A gene mutation. Median follow-up time was 23 months 
(range 6-48). Primary tumor was located in lower limb (38%) - mostly in femur and tibia, in 
upper limb (34%), and in pelvis/axial skeleton/ribs (28%).  110 (80%) patients had primary 
tumors, 28 (22%) recurrent tumors after previous surgical procedures (+/- radiotherapy). 
89/138 patients had locally advanced GCTB and underwent neoadjuvant denosumab. The 
median denosumab treatment duration was 8 months (median number of cycles 11), 98% 
had clinical benefit from therapy. 39 (44%) had wide en-bloc resection - WE (+ implantation 
of the prosthesis in 17 cases), the other 50 (56%) cases had intralesional curettage - C. 
Progression after surgical treatment was observed in 19 patients, 16 of them after C (32%); 
13 patients underwent  denosumab re-challenge, and all responded. Two-year progression-
free survival (PFS; from denosumab start) rate was 81%; 2-year EventFS (from surgery) was 
significantly better in WE group (93%) vs 55% in C group (p=0.006). Treatment was well 
tolerated with only 2 cases of grade 3 toxicity and one osteonecrosis of the jaw. 
Conclusion: Our retrospective study confirms that denosumab is extremely efficient in 
unresectable/metastatic disease as well as in a neoadjuvant  setting. Our data confirm 
excellent efficacy and short-term tolerability of this drug. Our data suggest that neoadjuvant 
therapy with denosumab is the option for treatment of initially locally advanced tumors to 
facilitate complete surgical resection or avoid mutilating surgery. The risk of recurrences after 
curettage of GCTB following denosumab raises questions about the optimal management of 
such cases. 
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Highlights: 
Denosumab is extremely efficient in unresectable/metastatic giant cell tumor (GCTB) of bone 
as well as in a neoadjuvant  setting.  
Our data confirm excellent efficacy and short-term tolerability of this drug.  
Our data suggest that neoadjuvant therapy with denosumab became the option for treatment 
of initially locally advanced tumors to facilitate complete surgical resection or avoid mutilating 
surgery.  
In cases in which we  expect to perform an enbloc surgery in a locally advanced GCTB 
denosumab is recommended preoperatively.  
The risk of recurrences after curettage of GCTB following denosumab raises questions about 
the optimal management. 
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Introduction  
Giant cell tumor of bone (GCTB) is an osteolytic, locally aggressive tumor,  
with low metastatic potential [1-5]. The pathogenesis of GCTB is related to RANK-
RANKL (receptor activator of nuclear factor kB ligand) interactions, because RANKL 
is highly expressed by neoplastic mononuclear mesenchymal stromal cells, whereas 
RANK on osteoclast-like cells, which are recruited secondarily in the tumor and 
responsible for the aggressive osteolytic activity [4,6-12]. The main treatment 
modality is surgery, mostly in the form of curettage, however the important challenge 
in the management of GCTB is relatively high local recurrence after primary therapy, 
especially in case of soft tissue extension of the tumor [2-4,13-15]. En bloc resection 
should be considered in case of multiple recurrent or locally advanced GCTB, 
impossible joint salvage, extensive cortex destruction (i.e., insufficient cortex left to 
curette), and extensive soft tissue involvement.  Until recently there were limited 
options in case of locally advanced/unresectable or metastatic disease. The 
introduction of denosumab – a RANKL inhibitor, revolutionized the medical therapy of 
surgically unsalvageable cases and its high efficacy was confirmed in two phase II 
clinical studies [15-18].  However, the long-term and real practice data of denosumab 
therapy, as well as the combination strategy with surgery, have not been not well 
explored [19-22]. 
In current study we analyzed a large series of GCTB patients treated with 
denosumab in real-life practice outside clinical trials in 6 European reference centers. 
Additionally, we have better evaluated the cohort of patients treated preoperatively 
with denosumab. 
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Patients and Methods 
Consecutive patients with histologically confirmed GCTB treated with denosumab in 
6 European referral centers (Warsaw, Poland; Birmingham, UK; Leiden, the 
Netherlands; Bologna, Italy; Milan, Italy; Prato and Careggi-Firenze, Italy) outside 
clinical trial between 2011 and 2016 with minimum 6 months of follow-up were 
included into the analysis. All pathological diagnoses were reviewed by an expert 
pathologist in the field of bone sarcomas in each center and confirmed by mutation in 
H3F3A gene when clinically indicated or per institution procedure. 
All cases were evaluated by multidisciplinary team (MDT) consisting of surgeon, 
orthopedic, medical oncologist, radiation oncologist and radiologist before start of 
therapy with denosumab. The study has been approved by the local Bio-Ethics 
Committee in Warsaw, Poland according to Good Clinical Practice Guidelines. 
Patients did not undergo any further selection. 
All patients were treated with subcutaneous injections of denosumab in dose 120 mg 
every 28 days, with additional doses on days 8 and 15 of the first month, with 
concurrent supplementation with Calcium 1000 mg/day and Vitamin D 400 IU/day. 
Treatment was conducted until the complete tumor resection was feasible (as 
assessed by MDT), tumor progression or unacceptable toxicity. Some patients on 
longer therapy had less dense schedule of denosumab injections: every 2-3 months. 
Tumor status was assessed every 3-6 months with computed tomography or 
magnetic resonance imagining, or plain X-ray according to local standards by 
dedicated expert radiologists from each center and by MTD when required. 
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89 patients (64%) at the data cut-off date had undergone surgery. 61 patients still 
continues denosumab therapy (twelve as rechallenge of a salvage therapy after 
tumor recurrence after surgery). 
Safety 
Adverse events were recorded and graded according to National Cancer Institute 
Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. 
Statistical analysis 
All statistical analyses were performed using the R language environment version 
3.3.3 (The R Foundation for Statistical Computing) statistical program. For the 
survival analysis, the Kaplan-Meier estimator was used with the log-rank tests for 
bivariate comparisons. The primary objective of the study was to assess the 
progression-free survival (PFS) of advanced GCTB patients treated with denosumab. 
PFS time was calculated from the date of the start of denosumab treatment to the 
date of the most recent follow-up, or progression of the disease defined according to 
modified Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1) [23] .  
The secondary objectives were based on the cohort of patients who underwent 
surgery after neoadjuvant  denosumab therapy, and comprised: type of surgery, 
relapse rate after surgery and the event-free survival (EFS) calculated from the date 
of surgery to the date of the most recent follow-up or relapse of the disease. Clinical 
benefit of denosumab therapy was defined as at least stabilization of the disease for 
no less than 6 months. The differences were considered statistically significant if the 
p-values were <0.05.  
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Results 
To the analysis 138 consecutive patients were included. Baseline patient 
characteristics are shown in Table I. Median age was 32 years. 
The lesions were located in lower limb (38%; n=52) mostly in femur (23%; n=32), in 
upper limb (34%; n=47) and in axial skeleton (28%; n=39). 
110 patients had newly diagnosed tumors with diagnostic biopsy only, 28 (20%) had 
recurrent tumors after previous surgical procedures (+/- radiotherapy). Twenty three 
cases (17%) were assessed as definitively unresectable , mostly in axial location, 
three cases (2%) were metastatic, all other patients had locally advanced tumors with 
soft tissue involvement (grade 3 according to Campanacci grading system), with 
penetration to the joint, pathological fracture, not amenable for limb-sparing surgery 
or with very high risk of tumor recurrence.  
Forty three pathologically cases were examined for mutation in H3F3A gene, all 
except three with positive results. 
Median follow-up time was 23 months (range: 6 – 55 months).  
Treatment outcomes in the entire group of patients 
The median denosumab treatment duration was 8 months (median number of cycles 
11, range 4-57). In patients, who had not yet had surgery (or those who were 
considered as definitively unresectable), and continued on denosumab, the median 
number of denosumab doses was 20 (postoperatively few patients were treated up to 
6 months). Treatment was well tolerated, only one case of osteonecrosis of the jaw 
was observed, which resolved with intervention and stopping denosumab therapy. In 
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two cases grade 3 toxicity was observed (hypophosphatemia and hypocalcemia). 
About 10% of patients (14) had grade II adverse events (Table II). 
Ninety eight percent of patients reached clinical benefit (at least stabilization of 
disease) from denosumab therapy mostly in the form of the calcification of the tumor 
[Fig. 1]. Three patients progressed early during denosumab treatment, two of them 
had applied radiotherapy 6.5 and 3 years earlier and high grade sarcoma was 
diagnosed 3 and 7 months after treatment start, none of them was tested for H3F3A 
mutation; two of them were initially considered unresectable, one was potentially 
resectable but with amputation only.  
In the cohort of patients with unresectable/metastatic disease no further disease 
progression was observed, so long-term disease control rate was 92.3%. 
Two-year PFS rate in the entire group of patients (including post-surgery relapses) 
was 81% (95% Cl 78%-91%), 3-year PFS rate was 71.4% (95% CI: 60.6%-84.1%) 
(Fig. 1). 
 
Treatment outcome for patients with locally advanced GCTB treated with 
neoadjuvant denosumab and surgery 
Eighty nine patients were treated surgically after preoperative denosumab, the 
characteristics of the group is presented in Table 1. The axial location consisted only 
small percentage of the group unlike patients with locally advanced 
unresectable/metastatic disease. Twenty three of 112 potentially resectable cases 
remained on denosumab therapy at the time of analysis and will be planned to 
surgery or patients did not decided for surgery yet. In this group of patients who 
underwent operation median number of cycles was lower than in the entire group - 8 
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cycles  (range: 4-16). Median time on denosumab before surgery was 6 months 
(range: 0.5-20.8 months). Patients who underwent prosthetic replacement had longer 
median preoperative duration of denosumab therapy as compared to patients 
undergoing surgery without prosthetic implantation. 17 patients received 
postoperatively denosumab up to 6 months at the decision of treating medical 
oncologist as indicated also in the phase II Amgen 20042006 study after pathological 
confirmation of partial or complete response.. 
The majority of cases - 50 patients (56%)  had intralesional curettage;  39 patients 
(44%) had wide en-block resection (+prosthesis replacement in 17 cases);; no 
extremity amputation was performed (Fig. 3,4). All patients were considered for 
surgical therapy after MDT decision and type of surgery was decided on the local 
extent of the disease and expected ability to achieve radical removal of the tumor 
with surgical procedure. 
Relapse rate (local recurrences only) after surgical treatment in neoadjuvant 
denosumab cohort was in 19 of 89 (21%) patients – in 16 of 50 patients after 
intralesional curettage (32%), and only in 3 of 39 patients after wide excision (7.7%; 
none after prosthetic replacement). The relapses were more common in recurrent 
GCTB at denosumab start 13 of 19 patients (68%) as compared to primary tumors - 5 
of 80 patients (7%).There were no differences among patients treated postoperative 
short-term denosumab and patients who interrupted therapy at surgery, altogether 
we observed disease relapses in 4 patients (23.5%) treated with adjuvant 
denosumab. 
Thirteen patients received rescue denosumab and all responded; six underwent the 
second surgery.  
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One-year event-free survival rate was 93% in patients who underwent wide excision 
and 77% in patients after curettage; two-year EFS rate was 93% in patients who 
underwent wide excision, as compared to 55% in group of patients after curettage 
(Fig. 2; p=0.006). 
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Discussion 
Our large multi-center series of advanced GCTB patients treated with denosumab 
outside clinical trials confirms that denosumab is active in both the neoadjuvant  and 
in the unresectable/metastatic cases, and it became the standard medical therapy in 
multidisciplinary management of GCTB [13,15,24]. We have presented excellent 
activity and short-term tolerability of this drug (Fig. 3, 4). The only three of 138 cases 
which progressed early on denosumab may constitute misdiagnosed high grade 
sarcomas from the beginning as they had not confirmed H3F3A mutational status 
[25], with positive anamnesis for radiotherapy exposure in 2 cases. This data 
reinforced the need for expert pathologist evaluation at the diagnosis of this rare 
disease. 
Our study comprises also the largest group of locally advanced GCTB treated in 
preoperative setting in combination with local surgery (Fig. 3,4, 5 suppl). The most 
important challenge for primary treatment of GCTB is the relatively high recurrence 
rate after curettage, especially when extensive soft tissue involvement by the tumor 
occurs  (21-65%). We also have observed high disease recurrence after curettage 
alone – it gives real concerns about curettage after denosumab as recurrence rate 
was as high as might have been expected  with surgery alone. On the other hand, in 
many of these cases curettage was not feasible before denosumab and this may 
constitute the benefit of denosumab in the group of patients who initially are not 
candidates for curettage. Nevertheless, we may suggest that if intralesional surgery 
is planned after neoadjuvant denosumab, drug therapy should be administered for 
relatively short period of time (approximately 3 months) – the calcified rim can be too 
thick after 3 months of denosumab precluding radical curettage of the tumor cells. 
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Moreover, the definitive conclusions are difficult because we have not any data from 
randomized study in such clinical situation. 
Our data may confirm also that when wide en-bloc resection is planned, especially 
with prosthetic replacement, longer preoperative therapy should be considered and 
the fully calcified tumor can facilitate or enable radical surgery, in our series we have 
observed excellent local control in such clinical scenario. We have to take into 
account, that all these tumors were very advanced locally with large soft tissue mass, 
penetration into the joint and/or with pathological fracture. Of course none of these 
features is per se an indication for denosumab therapy or extended resection and 
even in the case of pathological fracture curettage may be a reasonable option 
[26,27]. Nevertheless we present here consecutive series of patients who were 
assessed by experienced surgeons as initially ineligible for curettage or to achieve 
radical tumor excision or to perform limb-sparing surgery and they were referred to 
bone sarcoma expert centers for these reasons. A Canadian small prospective study 
remains in line of our observations that denosumab facilitates less aggressive 
surgical treatment, especially joint preservation, although recurrence rate was 
considerable [28]. 
The question if denosumab maintenance is necessary after surgery is still open. In 
the cohort of the phase II clinical trial 248 patients assessed for the effect of 
denosumab on planned surgery with observed downstaging in 157 patients that 
underwent surgery or no surgery in 91 patients [29]. Many patients received adjuvant 
denosumab for 6 months after surgery. Nevertheless, of the 157 patients who had 
surgery, local recurrence occurred in 34% of patients after curettage and - similarly to 
our data - in low percentage of cases (12%) after wide excision. For the same 
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reason, in selected cases with locally advanced tumors, denosumab alone might be 
preferred to denosumab combined with curettage. 
There are also several patients, who are definitively inoperable and will stay on 
denosumab therapy probably life-long. Although the tolerance of treatment was 
excellent, the data on the long-term use of denosumab for metastatic/unresectable 
GCTB are still limited [22,24]. The reduction of the frequency of administrations in 
patients who have achieved long-term stable disease on denosumab deserves 
further investigations and is subject to an European Organisation for Research and 
Treatment of Cancer (EORTC) study in development.  
 
Conclusions 
To summarize, denosumab therapy in GCTB is associated with a high rate of tumor 
control with excellent profile. Denosumab today is the gold standard medical 
treatment in the unresectable locally advanced or metastatic disease. Data suggest 
that neoadjuvant therapy with denosumab may become the option for treatment of 
initially locally advanced, high-risk tumors to facilitate surgical resection or avoid 
mutilating surgery. In cases in which we  expect to perform an en-bloc surgery in a 
locally advanced GCTB denosumab is recommended preoperatively, but the risk of 
recurrences after curettage of GCTB following denosumab therapy in these high risk 
tumors raises the question about the optimal duration of preoperative treatment, 
about the indication of denosumab when intralesional surgical treatment is planned 
approach, and it implies a careful selection of candidates to neoadjuvant denosumab 
and type of surgery planning in a multidisciplinary fashion. These questions should be 
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answered and they are worth investigating within prospective studies, which however 
are unlikely to be performed in the future. 
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Table 1. Patient characteristics. 
 The entire group  
N=138 (%) 
Surgically treated cohort 
after neoadjuvant therapy  
N = 89 (%) 
Gender 
 Male 
 Female 
 
55 (40%) 
83 (60%) 
 
35 (39%) 
54 (61%) 
Age – median (range) [years] 32 (14-81) 31 (15-70) 
Primary tumor location 
  Lower limb 
     Femur 
     Tibia 
   Pelvis/axial skeleton 
   Upper limb 
 
52 (38%) 
  32 (23%) 
  21 (15%) 
39 (28%) 
47 (34%) 
 
47  (52%) 
  18 (20%) 
  19 (21%) 
12 (13%) 
30 (34%) 
Primary tumor 
Recurrent tumor (after 
surgery +/- radiotherapy) 
 110 (80%) 
 28 (20%) 
 
80 
19 
Locally advanced, potentially 
resectable with mutilating 
surgery or with high risk of 
112 (81%) 
 
 
89  (100%) 
21 
 
disease recurrence 
Localized, definitively 
unresectable 
Metastatic 
 
23 (17%) 
3 (2%) 
Surgical procedure after 
Denosumab 
  Intralesional curretage  
  Wide en-block resection [+ 
implantation of the 
prosthesis] 
  
 
50 (56%) 
39 (44%) [17 (19%)] 
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Table 2. Adverse events during Denosumab therapy; n= 138 (%) 
  
Osteonecrosis of jaw (resolved) 1 (0.7) 
Grade 3, n (%) 2 (1.4) 
   Hypophosphatemia 1 (0.7) 
   Hypocalcemia 1 (0,7) 
Grade 2, n (%) 14 (10.1) 
   Hypophosphatemia 6 (4,3) 
   Hypocalcemia                                  
   Joints pain 
  Osteopenia 
4 (2.8) 
2 (1.4) 
1 (0.7) 
  Stress reaction 1 (0.7) 
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Fig. 1. Progression – free survival on denosumab therapy in the entire group of 
patients (including cases with post-surgery progression; from the date of start of 
denosumab therapy) [with 95%CI]. 
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Fig. 2. EFS according to post-denosumab type of surgery (calculated from the date of 
surgery; p-0.006) [with 95% CI] 
 
 
 
 
 
 
 
 
 
 
 Fig. 3. Recurrent GCTB of distant radius (after curretage), X
denosumab therapy, B - after 12 months of therapy, C 
with implantation of custom
A.    B.   
 
 
 
 
 
 
 
 
 
-rays: A 
- after radical wide resection 
-made prosthesis 
 C.  
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- before 
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Fig. 4. Response to denosumab therapy and curretage die to GCTB of distal radius 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 5. supplementary -  X-rays demonstrating response to denosumab therapy 
locally advanced GCTB of proximal humerus with pathological fracture.
 A. before therapy 
  B. after two months of therapy
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 C. after 6 months of therapy
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